Morgan Stanley
OLMA icon

Morgan Stanley’s Olema Pharmaceuticals OLMA Stock Holding History

Morgan Stanley’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1M Buy
1,215,690
+549,887
+83% +$12.2M ﹤0.01% 3048
2025
Q4 		$16.6M Sell
665,803
-890,084
-57% -$15.8M ﹤0.01% 3100
2025
Q3 		$15.2M Buy
1,555,887
+118,480
+8% +$711K ﹤0.01% 3153
2025
Q2 		$6.12M Buy
1,437,407
+985,716
+218% +$4.39M ﹤0.01% 3885
2025
Q1 		$1.7M Sell
451,691
-572,786
-56% -$2.88M ﹤0.01% 4708
2024
Q4 		$5.97M Buy
1,024,477
+774,876
+310% +$7.74M ﹤0.01% 3855
2024
Q3 		$2.98M Sell
249,601
-85,970
-26% -$1.1M ﹤0.01% 4371
2024
Q2 		$3.63M Sell
335,571
-162,555
-33% -$1.76M ﹤0.01% 4141
2024
Q1 		$5.64M Sell
498,126
-497,562
-50% -$6.42M ﹤0.01% 3823
2023
Q4 		$14M Buy
995,688
+944,162
+1,832% +$12.7M ﹤0.01% 3649
2023
Q3 		$636K Sell
51,526
-11,331
-18% -$115K ﹤0.01% 5055
2023
Q2 		$568K Sell
62,857
-51,033
-45% -$308K ﹤0.01% 5141
2023
Q1 		$395K Sell
113,890
-89,032
-44% -$363K ﹤0.01% 5391
2022
Q4 		$497K Sell
202,922
-84,582
-29% -$247K ﹤0.01% 5257
2022
Q3 		$793K Sell
287,504
-148,928
-34% -$632K ﹤0.01% 5017
2022
Q2 		$1.78M Sell
436,432
-168,828
-28% -$535K ﹤0.01% 4626
2022
Q1 		$2.58M Buy
605,260
+12,935
+2% +$71.3K ﹤0.01% 4330
2021
Q4 		$5.54M Buy
592,325
+506,201
+588% +$10.5M ﹤0.01% 3611
2021
Q3 		$2.37M Sell
86,124
-39,036
-31% -$1.05M ﹤0.01% 4429
2021
Q2 		$3.5M Buy
125,160
+63,702
+104% +$1.81M ﹤0.01% 4147
2021
Q1 		$2.04M Buy
61,458
+15,690
+34% +$672K ﹤0.01% 4244
2020
Q4 		$2.2M Buy
+45,768
New +$2.15M ﹤0.01% 4067

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley's OLMA Position: Q1 2026 in Review

Morgan Stanley increased its Olema Pharmaceuticals (OLMA) stake by 83% in Q1 2026, buying an estimated $12.2M and bringing the position to 1,215,690 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

Morgan Stanley first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Morgan Stanley held 1,215,690 shares of Olema Pharmaceuticals worth $18.1M as of Q1 2026.
  • Morgan Stanley bought 549,887 Olema Pharmaceuticals shares in Q1 2026, an estimated $12.2M.
  • Olema Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3048 holding.
  • Morgan Stanley first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.